Patents by Inventor Jiacheng Zhou

Jiacheng Zhou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210181742
    Abstract: A driving environment is perceived based on sensor data obtained from a plurality of sensors mounted on the ADV. In response to a request for changing lane from a first lane to a second lane, path planning is performed. The path planning includes identifying a first lane change point for the ADV to change from the first lane to the second lane in a first trajectory of the ADV, determining a lane change preparation distance with respect to the first lane change point, and generating a second trajectory based on the lane change preparation distance, where the second trajectory having a second lane change point delayed from the first lane change point. Speed planning is performed on the second trajectory to control the ADV to change lane according to the second trajectory with different speeds at different point in time.
    Type: Application
    Filed: December 12, 2019
    Publication date: June 17, 2021
    Inventors: JIACHENG PAN, JIAXUAN XU, JINYUN ZHOU, HONGYI SUN, SHU JIANG, JIAMING TAO, YIFEI JIANG, JIANGTAO HU, JINGHAO MIAO
  • Publication number: 20210181738
    Abstract: In one embodiment, a set of predetermined driving parameters is determined from a set of driving statistics data collected from a number of vehicles, which may be driven by human drivers. For each pair of the predetermined driving parameters, a distribution of the pair of driving parameters is plotted based on their relationship on a two-dimensional (2D) distribution space. The 2D distribution space is partitioned into a number of grid cells, each grid cell representing a particular pair of driving parameters. For each of the grid cells, a probability is calculated that the pair of driving parameter likely falls in the grid cell. A grid table is generated corresponding to the pair of driving parameters. The grid table can be utilized during the autonomous driving at real-time or during simulation to determine a ride stability of an autonomous driving vehicle (ADV) in view of the pair of driving parameters.
    Type: Application
    Filed: December 12, 2019
    Publication date: June 17, 2021
    Inventors: YIFEI JIANG, JINYUN ZHOU, JIACHENG PAN, JIAXUAN XU, HONGYI SUN, JIAMING TAO, SHU JIANG, JINGHAO MIAO, JIANGTAO HU
  • Publication number: 20210155605
    Abstract: The present invention relates to salt forms of the Pim kinase inhibitor N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of Pim kinase-related diseases such as cancer.
    Type: Application
    Filed: January 13, 2021
    Publication date: May 27, 2021
    Inventors: Zhongjiang Jia, Ganfeng Cao, Qiyan Lin, Yongchun Pan, Lei Qiao, Vaqar Sharief, Chongsheng Eric Shi, Michael Xia, Changsheng Zheng, Jiacheng Zhou, Qun Li
  • Publication number: 20210139022
    Abstract: In one embodiment, a process is performed during controlling Autonomous Driving Vehicle (ADV). A confidence level associated with a sensed obstacle is determined. If the confidence level is below a confidence threshold, and a distance between the ADV and a potential point of contact with the sensed obstacle is below a distance threshold, then performance of a driving decision is delayed. Otherwise, the driving decision is performed to reduce risk of contact with the sensed obstacle.
    Type: Application
    Filed: November 8, 2019
    Publication date: May 13, 2021
    Inventors: Jiaming TAO, Jiaxuan XU, Jiacheng PAN, Jinyun ZHOU, Hongyi SUN, Yifei JIANG, Jiangtao HU
  • Publication number: 20210139511
    Abstract: This application relates to solid forms and salt forms of the PD-1/PD-L1 inhibitor 4,4?-(((((2,2?-dichloro-[1,1?-biphenyl]-3,3?-diyl)bis(azanediyl))bis(carbonyl))bis(1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-2,5-diyl))bis(ethane-2,1-diyl))bis(bicyclo[2.2.1]heptane-1-carboxylic acid), including processes of preparation thereof, where the solid forms and salt forms are useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Application
    Filed: November 10, 2020
    Publication date: May 13, 2021
    Inventors: Zhongjiang Jia, Shili Chen, Yi Li, Timothy Martin, Bo Shen, Naijing Su, Jiacheng Zhou, Qun Li
  • Publication number: 20210128568
    Abstract: The present invention is directed to dihydrochloric acid and dibenzenesulfonic acid salts of the c-Met kinase inhibitor 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and pharmaceutical compositions thereof, useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways. The present invention further relates to processes and intermediates for preparing 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and salts thereof.
    Type: Application
    Filed: September 8, 2020
    Publication date: May 6, 2021
    Inventors: Lingkai Weng, Lei Qiao, Jiacheng Zhou, Pingli Liu, Yongchun Pan
  • Publication number: 20210105998
    Abstract: The present application relates to crystalline solid forms of an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: December 18, 2020
    Publication date: April 15, 2021
    Inventors: Shili Chen, Zhongjiang Jia, Pingli Liu, Lei Qiao, Yongzhong Wu, Jiacheng Zhou, Qun Li
  • Patent number: 10975085
    Abstract: The present invention is related to processes for preparing a composition comprising (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile, and related synthetic intermediate compounds. This compound is useful as an inhibitor of the Janus Kinase family of protein tyrosine kinases (JAKs) for treatment of inflammatory diseases, myeloproliferative disorders, and other diseases.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: April 13, 2021
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Jiacheng Zhou, James D. Rodgers, Haisheng Wang
  • Patent number: 10968200
    Abstract: The present invention relates to processes and intermediates for preparing 3-(cyanomethyl)-3-(4-{[(1R,2S)-2-phenylcyclopropyl]amino}piperidin-1-yl)azetidine-1-sulfonamide, and salts and solid forms thereof, which selectively modulate demethylase. Particular embodiments contemplate compounds and disease indications amenable to treatment by modulation of lysine specific demethylase-1 (LSD1).
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: April 6, 2021
    Assignee: Incyte Corporation
    Inventors: Zhongjiang Jia, Wayne Han, Yongchun Pan, Timothy Martin, Jiacheng Zhou, Qun Li
  • Publication number: 20210079016
    Abstract: The present invention relates to an amorphous solid form of (4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one, and processes for its preparation, which is an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and is useful in the treatment of various diseases such as cancer.
    Type: Application
    Filed: November 19, 2020
    Publication date: March 18, 2021
    Inventors: Shili Chen, William Frietze, Zhongjiang Jia, Pingli Liu, Jiacheng Zhou
  • Publication number: 20210040090
    Abstract: The present invention relates to salt forms of the PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3?-(3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-ylamino)-2,2?-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid, including methods of preparation thereof, where the compound is useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Application
    Filed: August 7, 2020
    Publication date: February 11, 2021
    Inventors: Zhongjiang Jia, Pingli Liu, David J. Meloni, Yongchun Pan, Yongzhong Wu, Jiacheng Zhou, Qun Li
  • Publication number: 20210030722
    Abstract: The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives.
    Type: Application
    Filed: April 15, 2020
    Publication date: February 4, 2021
    Inventors: Andrew P. Combs, Eddy W. Yue, Richard B. Sparks, Wenyu Zhu, Jiacheng Zhou, Qiyan Lin, Lingkai Weng, Tai-Yuen Yue, Pingli Liu
  • Publication number: 20210032203
    Abstract: The present disclosure relates to tosylate salts 1-{[4-(methoxymethyl)-4-({[(1R,2S)-2-phenylcyclopropyl]amino}methyl)piperidin-1-yl]methyl}cyclobutanecarboxylic acid, methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of the LSD1-associated or mediated diseases such as cancer.
    Type: Application
    Filed: June 12, 2020
    Publication date: February 4, 2021
    Inventors: Yongchun Pan, Wayne Han, Ganfeng Cao, William Frietze, Zhongjiang Jia, Vaqar Sharief, Jiacheng Zhou, Qun Li
  • Patent number: 10899736
    Abstract: This invention relates to processes and intermediates for making {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, useful in the treatment of diseases related to the activity of Janus kinases (JAK) including inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: January 26, 2021
    Assignee: Incyte Corporation
    Inventors: Dengjin Wang, Pingli Liu, Yongzhong Wu, Jiacheng Zhou
  • Patent number: 10858372
    Abstract: The present invention relates to an amorphous solid form of (4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one, and processes for its preparation, which is an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and is useful in the treatment of various diseases such as cancer.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: December 8, 2020
    Assignee: Incyte Corporation
    Inventors: Shili Chen, William Frietze, Zhongjiang Jia, Pingli Liu, Jiacheng Zhou
  • Publication number: 20200347065
    Abstract: The present application provides salt forms of N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide and N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which are useful as inhibitors of TAM kinases, as well as processes and intermediates related thereto.
    Type: Application
    Filed: March 19, 2020
    Publication date: November 5, 2020
    Inventors: Zhongjiang Jia, Yongzhong Wu, Yongchun Pan, Jiacheng Zhou, Qun Li
  • Patent number: 10799509
    Abstract: The present invention is directed to dihydrochloric acid and dibenzenesulfonic acid salts of the c-Met kinase inhibitor 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and pharmaceutical compositions thereof, useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways. The present invention further relates to processes and intermediates for preparing 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and salts thereof.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: October 13, 2020
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Lingkai Weng, Lei Qiao, Jiacheng Zhou, Pingli Liu, Yongchun Pan
  • Publication number: 20200283436
    Abstract: The present application relates to crystalline solid forms of an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: March 24, 2020
    Publication date: September 10, 2020
    Inventors: Shili Chen, Zhongjiang Jia, Pingli Liu, Lei Qiao, Yongzhong Wu, Jiacheng Zhou, Qun Li
  • Publication number: 20200270245
    Abstract: The present disclosure relates to solid forms of N-{[2?-(2,6-difluoro-3,5-dimethoxyphenyl)-3?-oxo-2?,3?-dihydro-1?H-spiro[cyclopropane-1,4?-[2,7]naphthyridin]-6?-yl]methyl}acrylamide, methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of the FGFR-associated or mediated diseases such as cancer.
    Type: Application
    Filed: February 6, 2020
    Publication date: August 27, 2020
    Inventors: Yongchun Pan, Chongsheng Eric Shi, Ming Tao, Wayne Han, Michael Xia, Dengjin Wang, Zhongjiang Jia, Jiacheng Zhou, Qun Li
  • Patent number: 10723700
    Abstract: The present disclosure relates to tosylate salts 1-{[4-(methoxymethyl)-4-({[(1R,2S)-2-phenylcyclopropyl]amino}methyl)piperidin-1-yl]methyl}cyclobutanecarboxylic acid, methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of the LSD1-associated or mediated diseases such as cancer.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: July 28, 2020
    Assignee: Incyte Corporation
    Inventors: Yongchun Pan, Wayne Han, Ganfeng Cao, Zhongjiang Jia, Jiacheng Zhou